Alix Alderman is vice president of regulatory affairs at PellePharm.
Prior to joining PellePharm, Alix led all regulatory aspects of global development and strategy for the rare bone disease programs at Ultragenyx as senior director of regulatory affairs. Prior to Ultragenyx, she served as global regulatory lead and director of global product strategy at Abbott/AbbVie. Previously, she held numerous positions of increasing responsibility at Amylin and InterMune, including regulatory affairs leadership for Amylin’s lipodystrophy, obesity and pramlintide early development and commercial franchise.
Alix is a member of The Organisation for Professionals in Regulatory Affairs (TOPRA) and has served for many years on the TOPRA Board of Directors.
She earned her bachelor’s degree in exercise physiology from the University of California at Davis.